conclus
rsv
infrequ
caus
ili
period
influenza
viru
circul
caus
sever
complic
hospit
adult
risk
factor
rsv
detect
adult
hospit
ili
includ
cancer
immunosuppress
treatment
specif
immun
antivir
therapi
might
benefit
patient
risk
p
loubet
clin
microbiol
infect
respiratori
syncyti
viru
pneumonia
adult
influenzalik
ill
influenza
elderli
b
r
c
object
aim
studi
analys
characterist
outcom
respiratori
syncyti
viru
rsv
infect
adult
hospit
influenzalik
ill
ili
method
patient
hospit
ili
includ
prospect
multicentr
studi
carri
six
french
hospit
three
consecut
influenza
season
rsv
respiratori
virus
detect
multiplex
pcr
nasopharyng
swab
risk
factor
rsv
infect
identifi
backward
stepwis
logist
regress
analysi
result
total
patient
hospit
ili
includ
year
underli
chronic
ill
rsv
detect
influenza
viru
risk
factor
rsv
infect
cancer
adjust
ci
p
immunosuppress
treatment
adjust
ci
p
patient
rsv
median
length
stay
day
complic
includ
pneumonia
respiratori
failur
fifteen
per
cent
admit
intens
care
unit
inhospit
mortal
rate
pneumonia
like
occur
patient
rsv
patient
rsvneg
ili
versu
p
influenza
viru
infect
versu
p
past
decad
respiratori
syncyti
viru
rsv
increasingli
recogn
import
pathogen
adult
especi
elderli
immunocompromis
patient
individu
underli
chronic
respiratori
diseas
elderli
popul
rsv
one
three
common
caus
respiratori
diseas
along
influenza
viru
rhinoviru
respiratori
viru
detect
improv
develop
highli
sensit
specif
molecular
method
provid
interest
new
epidemiolog
inform
howev
reason
cost
lack
rsvspecif
antivir
drug
adult
inpati
influenzalik
ill
ili
frequent
test
rsv
rather
test
influenza
viru
influenza
surveil
system
base
ili
acut
respiratori
ill
definit
unsuit
captur
case
rsv
children
adult
studi
need
determin
burden
rsv
infect
character
atrisk
popul
could
target
vaccin
antivir
treatment
aim
studi
describ
preval
b
clinic
featur
c
outcom
rsv
infect
adult
hospit
ili
analys
case
laboratoryconfirm
rsv
infect
three
consecut
influenza
season
post
hoc
analysi
patient
hospit
ili
fluvac
studi
fluvac
french
prospect
observ
studi
influenza
vaccin
efficaci
conduct
six
univers
hospit
cochin
hospit
pari
bichat
hospit
pari
pontchail
hospit
renn
limog
hospit
univers
hospit
montpelli
edouard
herriot
hospit
lyon
fluvac
studi
design
describ
rondi
et
al
loubet
et
al
season
enrol
take
place
period
influenza
circul
novemb
march
data
adult
hospit
least
h
ili
symptom
onset
day
sampl
collect
ili
defin
combin
follow
least
one
follow
system
symptom
fever
c
headach
myalgia
malais
b
least
one
follow
respiratori
symptom
cough
sore
throat
dyspnoea
particip
interview
nasopharyng
sampl
obtain
enrol
collect
demograph
characterist
chronic
underli
diseas
treatment
characterist
current
ili
episod
clinic
present
hospit
ward
length
hospit
stay
outcom
occurr
complic
intens
care
unit
admiss
death
data
retriev
medic
chart
interview
patient
famili
laboratori
databas
variabl
collect
detail
supplementari
materi
appendix
respiratori
virus
detect
nasopharyng
swab
patient
mean
multiplex
rtpcr
bronchoalveolar
lavag
fluid
sampl
tracheal
aspir
order
physician
charg
also
test
sampl
first
test
virolog
laboratori
particip
hospit
mean
realtim
influenza
b
pcr
manual
nucleic
acid
extract
sampl
sent
french
nation
influenza
refer
centr
cnrlyon
influenza
confirm
screen
respiratori
virus
rna
dna
extract
autom
easymag
system
biom
erieux
marci
letoil
franc
influenza
virus
detect
inhous
realtim
rtpcr
protocol
sampl
also
screen
panel
respiratori
virus
adenovirus
bocavirus
coronavirus
human
metapneumoviru
parainfluenza
virus
picornaviru
rsv
realtim
pcr
use
respiratori
multiwel
system
rgene
abi
analys
first
describ
characterist
patient
hospit
ili
univari
analysi
use
compar
rsvposit
patient
rsvneg
patient
includ
patient
infect
respiratori
virus
patient
free
viral
infect
b
influenza
virusposit
patient
quantit
variabl
express
mean
standard
deviat
sd
median
interquartil
rang
iqr
qualit
variabl
number
percentag
use
wilcoxon
rank
sum
test
fisher
exact
test
univari
comparison
miss
data
variabl
exclud
denomin
factor
associ
rsv
infect
identifi
use
rsvneg
individu
comparison
group
individu
influenza
viru
rsv
coinfect
exclud
analysi
use
backward
stepwis
logist
regress
model
rsv
test
result
positiveneg
depend
variabl
covari
p
valu
univari
analysi
test
multivari
model
name
age
consid
binari
variabl
year
dyspnoea
fever
myalgia
chronic
lung
diseas
cancer
solid
haematolog
malign
diabet
chronic
renal
failur
immunosuppress
treatment
factor
associ
pneumonia
onset
analys
among
ili
patient
individu
influenza
viru
rsv
coinfect
exclud
analysi
use
backward
stepwis
logist
regress
model
pneumonia
positiveneg
depend
variabl
covari
p
valu
univari
analysi
test
multivari
model
name
age
consid
continu
variabl
chronic
heart
diseas
chronic
respiratori
diseas
cancer
solid
haematolog
malign
diabet
chronic
renal
failur
immunosuppress
treatment
rsv
infect
influenza
viru
infect
influenza
vaccin
final
model
adjust
chronic
respiratori
diseas
age
known
role
onset
pneumonia
result
regress
model
express
odd
ratio
adjust
or
aor
ci
p
valu
consid
statist
signific
analys
use
stata
softwar
copyright
statacorp
lpt
colleg
station
tx
usa
fluvac
studi
clinicaltrialsgov
respect
good
epidemiolog
clinic
practic
clinic
research
declar
helsinki
approv
region
ethic
committe
studi
particip
gave
inform
consent
respiratori
viru
test
overal
patient
hospit
ili
includ
three
period
influenza
circul
fig
fig
respiratori
syncyti
viru
third
frequent
viru
influenza
viru
patient
ili
patient
least
one
viru
picornaviru
patient
ili
patient
least
one
viru
detect
virus
coronaviru
respect
human
metapneumoviru
adenoviru
bocaviru
six
patient
diagnos
influenza
viru
rsv
infect
remov
analys
median
age
patient
rsv
infect
alon
year
iqr
tabl
chronic
underli
diseas
present
case
consist
mainli
chronic
respiratori
diseas
chronic
heart
diseas
cancer
solid
tumour
haematolog
malign
fifteen
patient
immunosuppress
therapi
twentysix
patient
hospit
previou
year
averag
time
sd
median
time
symptom
onset
admiss
day
iqr
cough
fever
dyspnoea
main
symptom
patient
rsv
infect
median
length
hospit
stay
day
iqr
total
medic
complic
occur
patient
hospit
stay
includ
pneumonia
episod
complic
respiratori
failur
heart
failur
acut
respiratori
distress
syndrom
intens
care
unit
admiss
necessari
eight
patient
four
patient
die
hospit
stay
men
year
old
chronic
respiratori
diseas
furthermor
three
patient
chronic
heart
diseas
mean
time
admiss
death
day
sd
patient
rsv
older
patient
influenza
viru
year
iqr
versu
year
iqr
p
tabl
patient
rsv
like
cancer
immunosuppress
treatment
patient
without
rsv
respect
versu
p
versu
p
influenza
virusposit
patient
versu
p
versu
p
multivari
analysi
patient
ili
show
cancer
ci
p
immunosuppress
treatment
ci
p
significantli
associ
rsv
detect
tabl
patient
rsv
influenza
viru
infect
differ
term
length
stay
icu
admiss
mortal
adjust
chronic
respiratori
diseas
age
found
rsv
infect
ci
p
chronic
renal
failur
ci
p
activ
smoke
ci
p
significantli
associ
onset
pneumonia
tabl
studi
conduct
three
consecut
influenza
season
among
adult
hospit
ili
franc
rsv
third
common
respiratori
viru
detect
patient
compar
influenza
viru
rate
lower
found
usa
sundaram
latter
studi
rate
even
higher
among
hospit
patient
anoth
studi
falsey
et
al
report
preval
rsv
among
adult
age
year
underli
cardiopulmonari
diseas
admit
acut
respiratori
symptom
four
consecut
winter
rochest
ny
sever
reason
may
explain
broad
rang
report
rsv
detect
rate
exampl
studi
restrict
period
influenza
viru
circul
may
includ
peak
rsv
circul
although
enrol
two
studi
falsey
et
al
start
midnovemb
anoth
factor
age
includ
adult
year
wherea
sundaram
et
al
falsey
et
al
includ
older
subject
rsv
infect
may
frequent
furthermor
laboratori
method
use
rochest
studi
includ
viral
cultur
serolog
test
rtpcr
posit
test
twothird
case
final
clinic
definit
use
trigger
swab
collect
also
differ
among
studi
median
age
rsvinfect
patient
studi
year
contrari
studi
found
associ
rsv
infect
older
age
patient
rsv
infect
chronic
underli
condit
consist
mainli
chronic
respiratori
diseas
chronic
heart
diseas
consist
report
walsh
et
al
underli
pulmonari
diseas
signific
risk
factor
sever
rsv
ill
requir
hospit
found
two
underli
condit
independ
associ
rsv
infect
cancer
immunosuppress
treatment
associ
statist
signific
whether
rsvposit
patient
compar
rsvneg
patient
influenza
virusposit
patient
although
immunocompromis
patient
especi
patient
haematolog
malign
known
suscept
rsv
infect
solid
cancer
immunosuppress
therapi
classic
risk
factor
respiratori
syncyti
viru
associ
signific
morbid
median
length
hospit
stay
day
rsvinfect
patient
admit
intens
care
unit
die
find
consist
literatur
similar
percentag
note
influenza
group
studi
patient
rsv
significantli
like
patient
influenza
without
rsv
develop
pneumonia
versu
respect
falsey
et
al
lee
et
al
also
found
high
rate
pneumonia
among
rsvinfect
patient
year
admit
ili
usa
among
rsvinfect
adult
admit
three
hospit
hong
kong
jain
et
al
found
least
one
respiratori
viru
american
adult
communityacquir
pneumonia
requir
admiss
one
five
particip
hospit
rsv
found
patient
strength
studi
includ
larg
number
adult
hospit
ili
prospect
multicentr
design
standard
patient
screen
particip
centr
central
confirm
respiratori
virus
influenza
refer
centr
lengthi
studi
period
span
three
consecut
influenza
season
sever
limit
must
howev
acknowledg
first
particip
centr
teach
hospit
proport
patient
underli
diseas
may
higher
gener
ili
popul
owe
referr
bia
second
although
sampl
larg
studi
probabl
underpow
identifi
possibl
impact
rsv
morbid
mortal
multivari
analysi
third
ili
definit
use
captur
subset
rsv
infect
studi
reflect
real
burden
sever
rsv
infect
may
includ
clinic
manifest
fourth
report
post
hoc
result
fluvac
studi
design
answer
research
question
inde
fluvac
studi
design
assess
influenza
vaccin
efficaci
patient
enrol
period
influenza
viru
circul
differ
slightli
period
rsv
circul
mean
data
reflect
preval
rsv
among
patient
hospit
ili
period
influenza
viru
circul
peak
rsv
circul
usual
occur
earlier
owe
epidemiolog
interfer
howev
french
surveil
data
renal
system
show
peak
rsv
epidem
overlap
begin
influenza
viru
circul
three
season
interest
two
virus
cocircul
least
week
fig
conclus
prospect
observ
studi
conduct
franc
three
influenza
season
reveal
adult
hospit
ili
rsv
infect
develop
cardiopulmonari
complic
die
also
show
elderli
individu
patient
cancer
andor
immunosuppress
treatment
like
rsv
isol
hospit
ili
potenti
benefit
enhanc
rsv
test
antivir
treatment
vaccin
develop
group
consid
outcom
analys
rsv
infect
author
declar
compet
interest
relat
studi
launay
investig
clinic
trial
sponsor
janssen
compani
receiv
travel
support
attend
scientif
meet
pharmaceut
compani
current
work
receiv
fund
howev
studi
site
receiv
fund
sanofi
pasteur
sanofi
pasteur
msd
fluvac
studi
vaccin
produc
role
studi
design
data
analysi
decis
publish
prepar
manuscript
